Skip to main content
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
102.50
-0.14 (-0.14%)
At close: Aug 13, 2025, 4:00 PM
102.20
-0.30 (-0.29%)
Pre-market: Aug 14, 2025, 8:49 AM EDT

Boston Scientific Revenue by Segment
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
9.50B 8.90B 8.35B 7.80B 7.32B 6.97B 6.71B 6.49B
Cardiology Growth
29.86% 27.65% 24.40% 20.24% 15.81% 13.75% 13.08% 11.35%
Endoscopy
2.78B 2.72B 2.69B 2.64B 2.59B 2.55B 2.48B 2.41B
Endoscopy Growth
7.18% 6.67% 8.22% 9.68% 10.86% 12.35% 11.75% 9.06%
Peripheral Interventions
2.60B 2.49B 2.41B 2.30B 2.23B 2.18B 2.11B 2.05B
Peripheral Interventions Growth
16.43% 14.41% 14.27% 11.99% 12.09% 12.55% 11.12% 8.92%
Urology
2.47B 2.32B 2.20B 2.10B 2.05B 2.01B 1.96B 1.91B
Urology Growth
20.65% 15.54% 12.02% 9.56% 9.87% 9.79% 10.77% 10.19%
Neuromodulation
1.14B 1.12B 1.11B 1.08B 1.04B 998.00M 976.00M 956.00M
Neuromodulation Growth
10.14% 12.22% 13.22% 12.45% 9.28% 5.83% 6.32% 4.71%
Specialty Pharma
- - - - - - - - - - - - - - - - - 191.00M 219.00M 241.00M

Revenue by Geography
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
11.67B 10.91B 10.21B 9.53B 9.04B 8.68B 8.43B 8.20B
United States Growth
29.15% 25.71% 21.19% 16.25% 12.49% 10.49% 10.40% 10.14%
EMEA
3.33B 3.27B 3.23B 3.15B 3.05B 2.95B 2.86B 2.76B
EMEA Growth
9.26% 11.03% 13.06% 13.90% 13.75% 12.70% 13.02% 9.17%
APAC
2.86B 2.74B 2.69B 2.62B 2.54B 2.50B 2.40B 2.32B
APAC Growth
12.38% 9.56% 11.83% 12.75% 13.47% 16.50% 13.52% 8.56%
LACA
638.00M 631.00M 625.00M 618.00M 605.00M 583.00M 560.00M 534.00M
LACA Growth
5.45% 8.23% 11.61% 15.73% 19.33% 19.71% 19.66% 17.88%
Specialty Pharma
- - - - - - - - - - - - - - - - - 191.00M 219.00M 241.00M

Operating Expense Breakdown
Period Ending Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
6.49B 6.22B 5.98B 5.75B 5.43B 5.34B 5.19B 4.97B
Selling, General, and Administrative Growth
19.44% 16.45% 15.30% 15.62% 11.66% 14.20% 14.82% 10.29%
Research and Development
1.84B 1.69B 1.62B 1.52B 1.47B 1.44B 1.42B 1.38B
Research and Development Growth
25.07% 17.24% 14.20% 9.91% 7.55% 7.68% 6.95% 5.26%
Amortization
874.00M 862.00M 857.00M 840.00M 843.00M 840.00M 829.00M 820.00M
Amortization Growth
3.68% 2.62% 3.38% 2.44% 3.56% 3.96% 3.24% 3.02%
Asset and Goodwill Impairment
434.00M - 445.00M - 459.00M - - 190.00M 386.00M - - 457.00M 377.00M - 509.00M - -
Asset and Goodwill Impairment Growth
12.44% - -2.63% - 21.75% - - -62.67% -27.31% - - 4.58% -36.10% - - - -
Litigation-related Net Charges
- - - - - - - 190.00M - - 599.00M - 472.00M - 448.00M - 580.00M 505.00M - -
Litigation-related Net Charges Growth
- - - - - - - -67.24% - - 18.61% - - - - - - - - -
Restructuring Net Charges
105.00M 23.00M 16.00M 31.00M 38.00M 53.00M 70.00M 57.00M
Restructuring Net Charges Growth
176.32% -56.60% -77.14% -45.61% -17.39% 29.27% 180.00% 35.71%
Royalty Expense
43.00M 38.00M 34.00M 36.00M 42.00M 45.00M 46.00M 47.00M
Royalty Expense Growth
2.38% -15.56% -26.09% -23.40% -10.64% -2.17% -2.13% 4.44%
Loss on Disposal of Assets
- - - - - - - - - - 34.00M - - - 18.00M - - - - -
Contingent Consideration Net Expense
-24.00M -17.00M -5.00M 10.00M 45.00M 62.00M 57.00M 10.00M -
Contingent Consideration Net Expense Growth
- - - - 150.00% 77.14% 62.86% -80.00% -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.